-
Boston Scientific Expands Neuromodulation Portfolio with Axonics Acquisition
•
Boston Scientific Corporation (NYSE: BSX), a leading player in the medical device industry, has announced the completion of its acquisition of Axonics, Inc. (NASDAQ: AXNX) for a substantial USD 3.7 billion. This strategic transaction is set to bolster Boston Scientific’s presence in the field of sacral neuromodulation (SNM), enhancing the…
-
Boston Scientific Launches Vercisie Genius DBS System in China for Parkinson’s Disease Treatment
•
US major Boston Scientific Corporation (NYSE: BSX) has officially launched its Vercisie Genius, an implantable deep brain stimulation (DBS) system, at the 7th CIIE. This move is set to enhance the treatment options available to China’s growing Parkinson’s disease (PD) population. Parkinson’s Disease and Deep Brain Stimulation TherapyParkinson’s disease (PD),…
-
Boston Scientific Corporation Announces Acquisition of Cortex, Inc.
•
US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire Cortex, Inc., a medical technology company under the Ajax Health umbrella. The financial details of the agreement have not been disclosed, and the transaction is expected to close in the first half of…
-
Boston Scientific Reports 19.5% YOY Increase in Q3 Net Sales, Driven by New Product Launches and Market Expansion
•
Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced its financial results for the third quarter of 2024, highlighting a robust 19.5% year-on-year (YOY) increase in net sales, which reached USD 4.209 billion. The company’s business units reported significant growth, with MedSurg contributing USD…
-
Advancing Peripheral Artery Disease Care: Boston Scientific’s JETSTREAM Receives Marketing Nod in China
•
NEW YORK—Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical solutions, has secured a significant regulatory milestone with the National Medical Products Administration’s (NMPA) marketing approval for its JETSTREAM vascular plaque rotary cutting system. This development marks a significant step forward in the treatment of peripheral arterial disease (PAD)…
-
Boston Scientific Secures Silk Road Medical in a $1.16B Deal to Fortify Stroke Prevention Portfolio
•
Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical devices, has announced a definitive agreement to acquire all outstanding shares of Silk Road Medical Inc. (NSDQ: SILK) for a purchase price of USD 27.5 per share in cash. This transaction, with an overall value of USD 1.16 billion, is…
-
Boston Scientific’s FARAPULSE Pulse Field Ablation System Earns NMPA Approval
•
Boston Scientific Corporation (NYSE: BSX), a leading medical device company in the U.S., has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its FARAPULSE pulse field ablation system. This system includes the FARAWAVE disposable cardiac pulse field ablation catheter and the FARASTAR cardiac…
-
Cryofocus Biotechnology Partners with Boston Scientific for Respiratory Products Distribution in China
•
Cryofocus Biotechnology Co., Ltd (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced a strategic distribution agreement with the Shanghai subsidiary of US medical device giant Boston Scientific Corporation (NYSE: BSX). As per the terms of the agreement, Cryofocus is set to become the exclusive marketing partner and sales…
-
Boston Scientific Gets NMPA Approval for Agent DCB, First of Its Kind for Coronary ISR Treatment
•
Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Agent paclitaxel coated PTCA balloon catheter (AGENT DCB). This product is designed for the treatment of coronary in-stent restenosis (ISR)…
